“Considered by peers as ‘one of
the best generic Hatch-Waxman
litigation firms on the east coast.’”
– LMG Life Sciences
Visit our new blog at www.biosimilarsip.com
“Rothwell Figg is known for ‘meticulous patent drafting.’ Solely based in the capital, [Rothwell Figg] knows all the ins and outs of the D.C. scene and the USPTO.”
Post-Grant Trial Practice
“[This] compact yet heavy-hitting IP boutique has a client list that is the envy of many. Marquee names are drawn here for several compelling reasons: a persuasive win rate in high-stakes cases, the advanced technical backgrounds of its litigators, great comparative value and renowned expertise in post-grant procedures.”
Visit our new blog at www.ptablaw.com
Represented Mylan Pharmaceutical in an infringement claim made by Bristol-Myers Squibb related to the drug Buspar (buspirone).
Bristol-Myers motioned to dismiss antitrust counterclaims made by Mylan. The Court ruled a summary judgment of noninfringement. The court also denied Bristol’s motion and suing Mylan on it, as well as held that Bristol had acted in an objectively unreasonable fashion in listing the metabolite patent for buspirone in the Orange Book.
Bristol-Myers settled the antitrust claims by paying $535 million, including $35 million to Mylan after an initial ruling in favor of Mylan, 29 State Attorneys General, and several plaintiff class action groups who had joined Mylan’s suit.
company’s IP case
Patent troll CyberFone Systems LLC alleges Warner Bros. Entertainment Inc., CBS Interactive Inc., and dozens of other companies infringed a patent which covers a system of entering transaction data into databases because it covers an abstract concept rather than a specific invention.
The district court granted defendants motion for summary judgment that CyberFone’s patent was invalid under USC 101. Rothwell Figg took the lead in drafting and arguing the motion on behalf of the defendants. Rothwell Figg also took the lead in drafting and arguing against CyberFone’s appeal to the Federal Circuit.
February 2014, the three-judge Federal Circuit panel upheld the District of Delaware’s ruling that invalidated a software patent that CyberFone Systems LLC; alleged the 81 companies including CBS, CNN and Fox News infringed because it was not patent eligible under 35 USC 101.
Shaping a 360°
defense for leading
360° IP Performance
Rothwell Figg is a multifaceted intellectual property firm for high-stakes legal matters.
- Partner Steven Lieberman Quoted in BuzzFeed News Article On Jewish Texts Seized by Russia
A BuzzFeed News article on Russia's refusal to comply with a U.S. court order to return a collection of Jewish texts seized in the early 20th century contains quotes from Rothwell Figg partner Steven Lieberman, a lead…
- LMG Life Sciences Names Attorneys 2017 Life Sciences Stars; Recognizes Firm for Hatch-Waxman Patent Litigation
Rothwell Figg is proud to announce that four partners – E. Anthony Figg, Steven Lieberman, Joseph A. Hynds, and R. Danny Huntington – have been named 2017 Life Sciences Stars in Intellectual Property by LMG Life Sciences.…
- Associate Jennifer B. Maisel Featured in D.C. Bar Member Spotlight
Associate Jennifer B. Maisel was featured in the District of Columbia Bar's Member Spotlight series on October 2, 2017. With members in all 50 states and more than 80 countries, the new series by the D.C.…
- Rothwell Figg Elects Michael V. Battaglia and Seth E. Cockrum to Firm Partnership
Rothwell Figg is pleased to announce that Michael V. Battaglia and Seth E. Cockrum were named members of the firm effective October 1, 2017. “We are excited to welcome Michael and Seth, two extraordinary lawyers, into the firm’s…
- Alternative Dispute Resolution
- Biologics and Biosimilars
- Biology and Biotechnology
- Electrical and Computer
- Food and Drug Administration Practice
- Hatch-Waxman Litigation
- International Trade Commission
- Licensing and Transactions
- Media and Financial Services
- Patent Prosecution
- Post-Grant Trial Practice
- Software, E-Commerce and Business Methods
- Trademark Trial and Appeal Board
- Unfair Competition